Pharma commercial intelligence, news & analysis

Evaluate radically transforms your confidence in strategic portfolio decisions.

When you partner with Evaluate, our constantly expanding solutions and transparent methodologies and datasets are instantly at your disposal, along with expert, personalised support.

Evaluate provides a complete and dynamic valuation of pharma assets, turning understanding into insight, and insight into action.

HOW WE CAN HELP YOU

Market Reports

Thought Leadership

Read our wide range of complimentary market reports covering sector performance and valuation, market trends and global forecasts, including our annual Evaluate Pharma World Preview.

READ OUR REPORTS

OUR PRODUCTS

Evaluate Pharma

Get a global view of the pharmaceutical market’s past, present and future performance with over two decades of commercial data and consensus forecasts to 2026.

FIND OUT MORE

OUR SERVICES

Pharma Consulting & Analytics

Improve your strategic decision-making with customised, data-driven solutions that draw on our collaborative team of industry experts and trusted commercial intelligence.

FIND OUT MORE

June 03, 2023

Asco 2023 – Pfizer pushes forward in drug-resistant breast cancer

While Ibrance has been bested by class rivals, Pfizer is working on projects that might overcome CDK4/6 inhibitor resistance – though it is not alone.